BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21185785)

  • 1. On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies.
    Dellabona P; Casorati G; de Lalla C; Montagna D; Locatelli F
    Clin Immunol; 2011 Aug; 140(2):152-9. PubMed ID: 21185785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+ and CD4- subset dynamics and correlates with remission state.
    de Lalla C; Rinaldi A; Montagna D; Azzimonti L; Bernardo ME; Sangalli LM; Paganoni AM; Maccario R; Di Cesare-Merlone A; Zecca M; Locatelli F; Dellabona P; Casorati G
    J Immunol; 2011 Apr; 186(7):4490-9. PubMed ID: 21357532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults.
    Waller EK; Giver CR; Rosenthal H; Somani J; Langston AA; Lonial S; Roback JD; Li JM; Hossain MS; Redei I
    Blood Cells Mol Dis; 2004; 33(3):233-7. PubMed ID: 15528137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote
    Jahnke S; Schmid H; Secker KA; Einhaus J; Duerr-Stoerzer S; Keppeler H; Schober-Melms I; Baur R; Schumm M; Handgretinger R; Bethge W; Kanz L; Schneidawind C; Schneidawind D
    Front Immunol; 2019; 10():1542. PubMed ID: 31354710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison.
    Wang Y; Liu DH; Xu LP; Liu KY; Chen H; Chen YH; Han W; Shi HX; Huang XJ
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):821-30. PubMed ID: 20831895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation.
    Passweg JR; Koehl U; Uharek L; Meyer-Monard S; Tichelli A
    Best Pract Res Clin Haematol; 2006; 19(4):811-24. PubMed ID: 16997185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation.
    Locatelli F; Comoli P; Montagna D; Rossi F; Daudt L; Maccario R
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):479-92. PubMed ID: 15498718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors.
    Koh LP; Rizzieri DA; Chao NJ
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1249-67. PubMed ID: 17950913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation.
    Locatelli F; Vinti L; Palumbo G; Rossi F; Bertaina A; Mastronuzzi A; Bernardo ME; Rutella S; Dellabona P; Giorgiani G; Moretta A; Moretta L
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):339-49. PubMed ID: 21925087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
    Sinkovics JG
    Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
    Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF
    N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
    Michallet AS; Nicolini F; Michallet M
    Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells in the treatment of high-risk acute leukaemia.
    Locatelli F; Moretta F; Brescia L; Merli P
    Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients.
    Huang XJ
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):351-8. PubMed ID: 21925088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.